Vice President, Development

Gondola Bio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. Gondola Bio is an independent sister company to Bridge Bio, originally carved out in 2024 after securing $300M in private financing from external investors. Gondola Bio aims to leverage cutting-edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.

You are a development sciences leader who connects the dots from target engagement to first-in-human and early clinical proof of concept. You think in integrated development plans — pairing nonclinical pharmacology, DMPK, biomarkers, clinical pharmacology, and quantitative sciences into a coherent story that de-risks programs and accelerates decisions. You are hands‑on by default, energized by getting into the technical details and driving the work forward in a fast‑moving, early‑stage environment.

You partner naturally across Clinical Development, Regulatory, Research, and CMC, and you bring deep scientific judgment to genetic disease programs — ideally with direct experience advancing oligonucleotide and other novel modalities. Above all, you keep patients at the center of every development decision.

• Direct nonclinical PK/PD strategy spanning target engagement, pharmacodynamic response, and efficacy.
• Oversee in vitro and in vivo ADME and DMPK characterization to support candidate selection and IND‑enabling packages.

• Lead biomarker identification and the nonclinical‑to‑clinical biomarker strategy and execution.
• Drive clinical biomarker qualifications to support proof of mechanism and proof of concept.

• Own first-in-human through Phase 2 early clinical sciences and development strategy.
• Direct clinical pharmacology, including Phase 1 healthy‑volunteer and special‑population studies.

• Provide leadership across data analytics, pharmacometrics, biostatistics, and data management and data sciences to inform dose selection and program decisions.

• Oversee nonclinical and translational study execution and vendor management.
• Manage clinical pharmacology study execution and associated vendor relationships.

• Direct bioanalytical assay development for PK, biomarkers, and immunogenicity.
• Oversee nonclinical and clinical bioanalytical operations.

• Partner closely with Clinical Development, Global Regulatory Affairs, CMC, and Research to deliver integrated development plans and regulatory submissions (pre‑IND, IND, FIH, Phase 1/2).
• Personally drive the technical work across these functions, staying close to the science and the data while leveraging CROs and external partners to deliver, consistent with a lean, hands‑on early‑stage culture.
• Represent development sciences to senior leadership, the board, and external advisors, and contribute to portfolio‑level prioritization and resourcing decisions.

• PhD, PharmD, MD, or equivalent advanced degree in a relevant scientific discipline.
• Minimum 12+ years of biopharmaceutical drug development experience, including significant time in technical leadership roles.
• Substantial drug development experience spanning nonclinical through early clinical development, with a track record of advancing programs into and through first‑in‑human.
• Demonstrated leadership across two or more of the following: nonclinical pharmacology/DMPK, biomarkers, clinical pharmacology, quantitative sciences, bioanalytical sciences, or research operations.
• Experience operating in a lean, build‑oriented, clinical‑stage environment with significant reliance on CROs and external vendors.
• Thrives in a hands‑on, detail‑oriented capacity and is energized by driving the work forward directly.
• Strong record of cross‑functional partnership with Clinical Development, Regulatory, and CMC.

• Direct experience with oligonucleotide therapeutics (ASO, siRNA, GalNAc‑conjugated) or other…